New

Global ETF Survey 2026 Available: How 620 Professionals Select ETFs. Access the Report →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

Access the report

›ETF Issuers›Samsung Asset Management›244580

244580

Samsung KODEX Biotech ETF

Passive ETF Equity

Not rated

The 244580 Exchange Traded Fund (ETF) is provided by Samsung Asset Management. It is built to track an index: FnGuide Inc Bio Index. The 244580 ETF provides physical exposure, so by buying it you actually own parts of all the 50 underlying holdings. This share class generates a stream of income by distributing dividends.

₩7,535

-₩40 (-0.53%) 2 days ago

12:00 AM 10/23/26 Closed

1D price range

₩7,330₩7,560

52W price range

₩6,775₩14,330

YTD Perf.

-39.47%

YTD Flows

Annualized volatility

Fund AuM

€135M

Share class AuM

€135M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

KR7244580007

TER

0.45%

Inception date

5/12/2016

Issuer

Samsung Asset Management

Benchmark

FnGuide Inc Bio Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
261070 Mirae Asset TIGER KOSDAQ150 BIOTECH ETF	+7.13%
253280 RISE Healthcare ETF	+4.83%
143860 Mirae Asset TIGER HEALTH CARE ETF	+6.57%
266420 Samsung KODEX Healthcare ETF	+6.58%
461450 SAMSUNG Kodex KOSDAQ Global ETF	-0.98%

API

PerformanceDec 30, 2025 - Oct 22, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 08/31/26

Healthcare

94.30%

Consumer Non-Cyclicals

1.83%

Non-Energy Materials

1.83%

Industrials

1.70%

Unavailable

0.34%

Latest 244580 news

No content available for this fund

FAQ about 244580

244580 is a Passive ETF. This ETF provides exposure to Equally Weighted South Korean Biotechnology Equities.

244580 tracks the FnGuide Inc Bio Index - KRW, through a full replication replication method.

244580 carries a total expense ratio (TER) of 0.45%, indicating the annual cost for holding the fund.

244580 was introduced to the market on May 12, 2016. It trades on South Korea

Samsung KODEX Biotech ETF, 244580, is provided by Samsung Asset Management. Learn more about Samsung Asset Management here.

244580 oversees €135M in assets as of October 22, 2026.

244580 follows a distributing dividend policy, meaning it pays out income to investors.

As of August 31, 2026, 244580 has significant geographic allocations in Republic of Korea.

As of August 31, 2026, 244580 focuses largely on Healthcare, Consumer Non-Cyclicals and Non-Energy Materials.

As of August 31, 2026, 244580 holds 50 positions in its portfolio, with 39.36% of assets concentrated in its top 15 holdings.

As of August 31, 2026, 244580 top three holdings include Hanmi Science Co., Ltd., PharmaResearch Co., Ltd. and Hanmi Pharmaceutical Co., Ltd..

The base currency of 244580 is KRW.

Top 10 holdings

Data as of 08/31/26

Hanmi Science Co., Ltd.

3.41%

PharmaResearch Co., Ltd.

3.36%

Hanmi Pharmaceutical Co., Ltd.

2.73%

DongKook Pharmaceutical Co., Ltd.

2.67%

SAMSUNG BIOLOGICS Co., Ltd.

2.66%

Alteogen, Inc.

2.60%

Celltrion, Inc.

2.59%

Onconic Therapeutics, Inc.

2.58%

HANALL BIOPHARMA Co., Ltd.

2.56%

Yuhan Corp.

2.49%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

Samsung KODEX Biotech ETF

FAQ about 244580

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US